Evaxion to develop tailored novel cancer vaccines based upon a new untapped source of ai-discovered targets

Copenhagen, denmark, jan. 24, 2024 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) ("evaxion" or the "company"), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, announces an expanded commitment to developing tailored cancer vaccines by targeting a novel category of ai-identified tumor antigens, named endogenous retroviruses (ervs).
EVAX Ratings Summary
EVAX Quant Ranking